BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 16908934)

  • 1. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
    Guarneri V; Lenihan DJ; Valero V; Durand JB; Broglio K; Hess KR; Michaud LB; Gonzalez-Angulo AM; Hortobagyi GN; Esteva FJ
    J Clin Oncol; 2006 Sep; 24(25):4107-15. PubMed ID: 16908934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
    Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
    Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
    Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
    J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
    Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
    Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
    Bengala C; Zamagni C; Pedrazzoli P; Matteucci P; Ballestrero A; Da Prada G; Martino M; Rosti G; Danova M; Bregni M; Jovic G; Guarneri V; Maur M; Conte PF;
    Br J Cancer; 2006 Apr; 94(7):1016-20. PubMed ID: 16570045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
    de Azambuja E; Procter MJ; van Veldhuisen DJ; Agbor-Tarh D; Metzger-Filho O; Steinseifer J; Untch M; Smith IE; Gianni L; Baselga J; Jackisch C; Cameron DA; Bell R; Leyland-Jones B; Dowsett M; Gelber RD; Piccart-Gebhart MJ; Suter TM
    J Clin Oncol; 2014 Jul; 32(20):2159-65. PubMed ID: 24912899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
    Venturini M; Bighin C; Monfardini S; Cappuzzo F; Olmeo N; Durando A; Puglisi F; Nicoletto O; Lambiase A; Del Mastro L
    Breast Cancer Res Treat; 2006 Jan; 95(1):45-53. PubMed ID: 16267615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
    Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
    J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
    Procter M; Suter TM; de Azambuja E; Dafni U; van Dooren V; Muehlbauer S; Climent MA; Rechberger E; Liu WT; Toi M; Coombes RC; Dodwell D; Pagani O; Madrid J; Hall M; Chen SC; Focan C; Muschol M; van Veldhuisen DJ; Piccart-Gebhart MJ
    J Clin Oncol; 2010 Jul; 28(21):3422-8. PubMed ID: 20530280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
    Suter TM; Procter M; van Veldhuisen DJ; Muscholl M; Bergh J; Carlomagno C; Perren T; Passalacqua R; Bighin C; Klijn JG; Ageev FT; Hitre E; Groetz J; Iwata H; Knap M; Gnant M; Muehlbauer S; Spence A; Gelber RD; Piccart-Gebhart MJ
    J Clin Oncol; 2007 Sep; 25(25):3859-65. PubMed ID: 17646669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment.
    Ewer MS; Vooletich MT; Durand JB; Woods ML; Davis JR; Valero V; Lenihan DJ
    J Clin Oncol; 2005 Nov; 23(31):7820-6. PubMed ID: 16258084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer.
    Russo G; Cioffi G; Gori S; Tuccia F; Boccardi L; Khoury G; Lestuzzi C; Maurea N; Oliva S; Faggiano P; Tarantini L;
    J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):141-6. PubMed ID: 24534802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
    Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
    J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
    Telli ML; Hunt SA; Carlson RW; Guardino AE
    J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
    Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
    J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer.
    Venturini M; Bighin C; Puglisi F; Olmeo N; Aitini E; Colucci G; Garrone O; Paccagnella A; Marini G; Crinò L; Mansutti M; Baconnet B; Barbato A; Del Mastro L
    Breast; 2010 Oct; 19(5):333-8. PubMed ID: 20185313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.
    Tarantini L; Cioffi G; Gori S; Tuccia F; Boccardi L; Bovelli D; Lestuzzi C; Maurea N; Oliva S; Russo G; Faggiano P;
    J Card Fail; 2012 Feb; 18(2):113-9. PubMed ID: 22300778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
    Dang C; Fornier M; Sugarman S; Troso-Sandoval T; Lake D; D'Andrea G; Seidman A; Sklarin N; Dickler M; Currie V; Gilewski T; Moynahan ME; Drullinsky P; Robson M; Wasserheit-Leiblich C; Mills N; Steingart R; Panageas K; Norton L; Hudis C
    J Clin Oncol; 2008 Mar; 26(8):1216-22. PubMed ID: 18323546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy.
    Cao L; Hu WG; Kirova YM; Yang ZZ; Cai G; Yu XL; Ma JL; Guo XM; Shao ZM; Chen JY
    Cancer Radiother; 2014 Mar; 18(2):119-24. PubMed ID: 24642505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.
    Martín M; Esteva FJ; Alba E; Khandheria B; Pérez-Isla L; García-Sáenz JA; Márquez A; Sengupta P; Zamorano J
    Oncologist; 2009 Jan; 14(1):1-11. PubMed ID: 19147689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.